{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:19:59Z","timestamp":1761625199628,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.dld.2020.06.037","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T07:45:19Z","timestamp":1595231119000},"page":"1164-1169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide"],"prefix":"10.1016","volume":"52","author":[{"given":"Luisa","family":"Roade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Loglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Riveiro-Barciela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Soffredini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriana","family":"Facchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanai","family":"di Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2020.06.037_bib0001","unstructured":"World Health Organisation. Global Hepatitis Report, 2017.; 2017."},{"key":"10.1016\/j.dld.2020.06.037_bib0002","doi-asserted-by":"crossref","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. 2016;388(10049):1081-1088. doi:10.1016\/S0140-6736(16)30579-7.The","DOI":"10.1016\/S0140-6736(16)30579-7"},{"issue":"12","key":"10.1016\/j.dld.2020.06.037_bib0003","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: a modelling study","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"21","key":"10.1016\/j.dld.2020.06.037_bib0004","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.dld.2020.06.037_bib0005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"volume":"10","year":"2016","author":"Sarin","key":"10.1016\/j.dld.2020.06.037_bib0006"},{"issue":"4","key":"10.1016\/j.dld.2020.06.037_bib0007","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance american association for the study of liver diseases","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.dld.2020.06.037_bib0008","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten\u2010year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2020.06.037_bib0009","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/liv.13641","article-title":"Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B","volume":"38","author":"Buti","year":"2018","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.dld.2020.06.037_bib0010","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int"},{"issue":"9865","key":"10.1016\/j.dld.2020.06.037_bib0011","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.dld.2020.06.037_bib0012","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2020.06.037_bib0013","doi-asserted-by":"crossref","DOI":"10.1086\/655681","article-title":"Systematic review and meta\u2010analysis: renal safety of tenofovir disoproxil fumarate in HIV\u2010infected patients","author":"Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.dld.2020.06.037_bib0014","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/MCG.0000000000000569","article-title":"Altered underlying renal tubular function in patients with chronic hepatitis B receiving nucleos(t)ide analogs in a real-world setting the MENTE study","volume":"50","author":"Rodriguez-Novoa","year":"2016","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2020.06.037_bib0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u202fweeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2020.06.037_bib0016","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO)z","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.dld.2020.06.037_bib0017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.dld.2020.06.037_bib0018","article-title":"Effect of tenofovir on renal function in patients with chronic hepatitis B","author":"Jung","year":"2018","journal-title":"Med (United States)"},{"key":"10.1016\/j.dld.2020.06.037_bib0019","unstructured":"Eurostat. Population structure and ageing - Statistics Explained. Population structure and ageing. doi:http:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php\/Population_structure_and_ageing"},{"issue":"1","key":"10.1016\/j.dld.2020.06.037_bib0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-019-1126-1","article-title":"Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials","volume":"8","author":"Wong","year":"2019","journal-title":"Syst Rev"},{"key":"10.1016\/j.dld.2020.06.037_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years-of therapy","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2020.06.037_bib0022","doi-asserted-by":"crossref","unstructured":"Cathcart AL, Lik-Yuen Chan H, Bhardwaj N, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection. 2018. doi:10.1128\/AAC","DOI":"10.1136\/gutjnl-2018-IDDFabstracts.207"},{"key":"10.1016\/j.dld.2020.06.037_bib0023","unstructured":"VEMLIDY. 02\/2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208464s007lbl.pdf. Published 2015."},{"key":"10.1016\/j.dld.2020.06.037_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(18)30296-0","article-title":"Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial","author":"Eron","year":"2019","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.dld.2020.06.037_bib0025","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1016\/S2352-3018(19)30195-X","article-title":"Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m","volume":"6","author":"Maggiolo","year":"2019","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.dld.2020.06.037_bib0026","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jvh.13053","article-title":"Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"26","author":"Fong","year":"2019","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.dld.2020.06.037_bib0027","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2020.06.037_bib0028","unstructured":"Lik H, Chan Y, Korea S, et al. 3-year efficacy and safety of tenofovir alafenamide compared with tenofovir disoproxil fumarate in HBeAg-negative and -positive patients with chronic hepatitis B. In: AASLD 2018. San Francisco; 2018."},{"key":"10.1016\/j.dld.2020.06.037_bib0029","doi-asserted-by":"crossref","unstructured":"Buti M, Izumi N, Lim Y-S, et al. Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment. In: AASL 2019: The Liver Meeting. Boston; 2019. doi: 10.1016\/S0618-8278(19)30903-X","DOI":"10.1016\/S0618-8278(19)30903-X"},{"key":"10.1016\/j.dld.2020.06.037_bib0030","unstructured":"NCT02862548. Efficacy and safety of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF)-containing regimens in participants with chronic hepatitis B virus (HBV) infection and stage 2 or greater chronic kidney disease who have received a liver transp. https:\/\/clinicaltrials.gov\/show\/NCT02862548. 2016. ClinicalTrials.gov."},{"key":"10.1016\/j.dld.2020.06.037_bib0031","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2036.2012.05093.x","article-title":"Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B","author":"Gara","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2020.06.037_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.11.021","article-title":"Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection","volume":"13","author":"Mallet","year":"2015","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865820303224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865820303224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:13:49Z","timestamp":1761624829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865820303224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1590865820303224"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2020.06.037","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2020.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}